Biochemical and immunologic mechanisms in atopic dermatitis: New targets for emerging therapies
- 1 July 1999
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 41 (1) , 72-77
- https://doi.org/10.1016/s0190-9622(99)70410-x
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- The Mechanism of Action of Cyclosporin A and FK506Clinical Immunology and Immunopathology, 1996
- Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1993
- Increased Interleukin-4 Production by Atopic Mononuclear Leukocytes Correlates with Increased Cyclic Adenosine Monophosphate – Phosphodiesterase Activity and Is Reversible by Phosphodiesterase InhibitionJournal of Investigative Dermatology, 1993
- Recombinant interferon gamma therapy for atopic dermatitisJournal of the American Academy of Dermatology, 1993
- Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.Thorax, 1991
- Transfer of Allergen-Specific IgE-Mediated Hypersensitivity with Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1988
- Dermal Deposition of Eosinophil-Granule Major Basic Protein in Atopic DermatitisNew England Journal of Medicine, 1985
- Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP—agonist hyporesponsivenessJournal of Allergy and Clinical Immunology, 1982
- Heterologous desensitization of leukocytes: a possible mechanism of beta adrenergic blockade in atopic dermatitisJournal of Allergy and Clinical Immunology, 1981
- Wheal and erythema allergy in patients with agammaglobulinemiaJournal of Allergy, 1962